ClinicalTrials.gg
Status unknownNCT03259672Updated Aug 24, 2017

Influence of Sevoflurane and Desflurane on Postoperative Sore Throat

An interventional study of Sevoflurane and Desflurane in Hip Arthroplasty, sponsored by Keimyung University Dongsan Medical Center. Status unknown. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-08-24.

Primary conditionPharyngitis(the registry's first term)UnverifiedIs this wrong?The registry often attaches Pharyngitis to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Keimyung University Dongsan Medical Center · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Aug 2017), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This investigation is planned to compare the incidence and severity of postoperative sore throat according to the use of sevoflurane or desflurane.

02

Conditions studied

  • Hip Arthroplasty

Browse trials for

Keywords

  • intubation
  • pharyngitis
  • remifentanil
03

In context

Pharyngitis Unverified

226 studies on the registry are indexed under Pharyngitis; 35 are open to participants now.

This study's planned enrollment of 100 is below the median of 144 across 188 interventional studies indexed under Pharyngitis.

Browse Pharyngitis studies →

Lead sponsor

Keimyung University Dongsan Medical Center is the lead sponsor of 86 studies on the registry; 11 are open to participants now.

Compared within Pharyngitis, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients scheduled for general anesthesia with endotracheal intubation

Exclusion criteria

Exclusion Criteria:

  • Difficult airway
  • Friable teeth
  • Rapid sequence induction
  • Recent sore throat
  • Recent upper respiratory infection
  • Asthma
  • Chronic cough
  • Arrhythmia
  • Coronary disease
  • Heart failure
  • Pregnancy
  • Allergy to sevoflurane
  • Allergy to desflurane
  • Fever after halogenated anesthetics
  • Jaundice after halogenated anesthetics
  • Malignant hyperthremia
  • Allergy to remifentanil
  • Friable teeth
  • History of head and neck surgery
  • Multiple intubation attempts
  • Regional anesthetic agents
  • Gastric tube
  • Dexamethasone
  • Severe hypovolemia
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Sevoflurane

    Drug: Sevoflurane

  • Experimental
    Desflurane

    Drug: Desflurane

Interventions

  • Sevoflurane was used as a maintenance anesthetic agent.

  • Desflurane was used as a maintenance anesthetic agent.

06

What researchers measure

Primary outcomes

  1. Number of participants with postoperative sore throat

    Time frame: At 24 hr

Secondary outcomes

  1. Number of participants with postoperative sore throat

    Time frame: At 0, 2, 4 and 24 hr

  2. Number of participants with postoperative hoarseness

    Time frame: At 0, 2, 4 and 24 hr

  3. Number of participants with postoperative cough

    Time frame: At 0, 2, 4 and 24 hr

  4. Number of participants with postoperative nausea

    Time frame: At 0, 2, 4 and 24 hr

  5. Number of participants with postoperative vomiting

    Time frame: At 0, 2, 4 and 24 hr

  6. Number of participants with additional pain medication

    Time frame: At 0, 2, 4 and 24 hr

  7. Visual analogue scale of postoperative pain

    Time frame: At 0, 2, 4 and 24 hr

  8. Number of participants with shivering

    Time frame: At 0, 2, 4 and 24 hr

  9. Requirements of analgesics

    Time frame: At 0, 2, 4 and 24 hr

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2017; primary completion for Oct 2018, 12 months later.

Of 58 non-industry interventional studies with no phase under Pharyngitis, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's planned 12 months is above that.

Counting every sponsor, half of 63 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2017
First posted
Aug 24, 2017
StartEst.
Oct 1, 2017
Primary completionEst.
Oct 1, 2018
CompletionEst.
Nov 1, 2018
Last update
Aug 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03259672
Lead sponsor
Keimyung University Dongsan Medical Center
Responsible party
Hyun-Chang Kim (Assistant professor, Keimyung University Dongsan Medical Center) — Principal investigator
First posted
Aug 24, 2017
Start date
Oct 1, 2017 (estimated)
Primary completion
Oct 1, 2018 (estimated)
Completion
Nov 1, 2018 (estimated)
Last update
Aug 24, 2017

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Desflurane

Start the discussion